Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in CPI-pretreated advanced renal cell carcinoma
NCT03463681Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Jun 2018
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in renal cell carcinoma (RCC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Started Jun 2018; status: completed.
02
Drugs
cabozantinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03463681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03463681.